Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 13/20 | 0.52 |
| ▸ | CACNA1C | Q13936 | 6/20 | 0.52 |
| ▸ | CACNA1B | Q00975 | 6/20 | 0.52 |
| ▸ | CACNA1G | O43497 | 5/20 | 0.52 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30822919 | 0.92 | CACNA1H (0.50) | CACNA1HCACNA1CCACNA1BCACNA1GEGLN1 | |
| SCHEMBL32674500 | 0.91 | CACNA1H (0.49) | CACNA1HCACNA1CCACNA1BCACNA1GEGLN1 | |
| SCHEMBL30822926 | 0.90 | CACNA1H (0.51) | CACNA1HCACNA1CCACNA1BCACNA1GEGLN1 | |
| SCHEMBL30822907 | 0.88 | CACNA1H (0.55) | CACNA1HCACNA1CCACNA1BCACNA1GEGLN1 | |
| SCHEMBL4165936 | 0.87 | KDR (0.58) | CACNA1HCACNA1CCACNA1BCACNA1G | |
| SCHEMBL30822893 | 0.85 | HTT (0.55) | CACNA1HCACNA1CCACNA1BCACNA1GDYRK1A | |
| SCHEMBL30822887 | 0.84 | MTOR (0.44) | DYRK1ADYRK1B | |
| SCHEMBL30822898 | 0.84 | CACNA1H (0.51) | CACNA1HCACNA1CCACNA1BCACNA1GEGLN1 | |
| SCHEMBL32674483 | 0.83 | TAAR1 (0.47) | CACNA1HCACNA1CCACNA1BCACNA1GEGLN1 | |
| SCHEMBL30822929 | 0.82 | CACNA1H (0.60) | CACNA1HCACNA1CCACNA1BCACNA1GEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042743-A1 | SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES | COUNCIL SCIENT IND RES (IN) | 2026-02-12 | — | — | US | claimed |
| EP-4565566-A1 | SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES | Council of Scientific and Industrial Research, an Indian Registered Body Incorporated under Regn. of Soc. Act (Act XXI of 1860) (IN) | 2025-06-11 | — | — | EP | claimed |
| WO-2024028893-A1 | SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2024-02-08 | — | — | WO | claimed |
| US-20260042743-A1 | SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES | COUNCIL SCIENT IND RES (IN) | 2026-02-12 | — | — | US | disclosed |
| EP-4565566-A1 | SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES | Council of Scientific and Industrial Research, an Indian Registered Body Incorporated under Regn. of Soc. Act (Act XXI of 1860) (IN) | 2025-06-11 | — | — | EP | disclosed |
| WO-2024028893-A1 | SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2024-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042743-A1 | SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES | ACE2, SARS1, NR3C2 | CACNA1H 1849/4885CACNA1C 1701/4885CACNA1B 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.